ProKidney Corp. (NASDAQ:PROK – Get Free Report) SVP Darin J. Weber sold 17,238 shares of ProKidney stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $2.50, for a total value of $43,095.00. Following the sale, the senior vice president now directly owns 172,432 shares of the company’s stock, valued at approximately $431,080. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
ProKidney Stock Up 4.4 %
PROK stock opened at $2.84 on Thursday. ProKidney Corp. has a 52-week low of $1.12 and a 52-week high of $13.51. The company’s 50-day simple moving average is $1.56 and its 200-day simple moving average is $1.80. The firm has a market cap of $651.33 million, a P/E ratio of -4.98 and a beta of 1.08.
ProKidney (NASDAQ:PROK – Get Free Report) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.10. On average, analysts anticipate that ProKidney Corp. will post -0.65 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ProKidney
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on PROK shares. Bank of America lowered shares of ProKidney from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Morgan Stanley assumed coverage on ProKidney in a report on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 price target for the company.
View Our Latest Stock Analysis on PROK
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
See Also
- Five stocks we like better than ProKidney
- How to invest in marijuana stocks in 7 stepsĀ
- United Airlines Soars on Earnings Beat
- Investing in large cap stocks: Diving into big caps
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What Do S&P 500 Stocks Tell Investors About the Market?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.